ATHE

Alterity Therapeutics Ltd ADR

Jan 30 • 04:00PM ET

3.17

-0.09 -2.76 %

Healthcare • Biotechnology • Australia • NASD

Jan 30, 7:30 AMAlterity Therapeutics issues its Q2 FY26 Appendix 4C cash flow report and corporate update, highlighting a strong cash position, strengthened Phase 2 ATH434 efficacy analyses in MSA, and well-advanced planning for a pivotal Phase 3 program with a targeted End-of-Phase-2 FDA meeting in mid-2026.

Peers: BIIB ABBV PRTA ACAD SAVA IONS ANVS INMB LXRX CYPH

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.74	Insider Own	4.67%	Shs Outstand	18.13M	Perf Week	-10.70%
Market Cap	57.47M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	0.00%	Shs Float	17.28M	Perf Month	3.59%
Enterprise Value	30.92M	PEG	-	EPS next Q	-0.40	Inst Own	1.85%	Short Float	0.00%	Perf Quarter	-32.55%
Income	-7.90M	P/S	-	EPS this Y	46.61%	Inst Trans	309.07%	Short Ratio	0.02	Perf Half Y	-40.64%
Sales	0.00M	P/B	1.74	EPS next Y	0.00%	ROA	-36.73%	Short Interest	0.00M	Perf YTD	2.92%
Book/sh	1.83	P/C	2.16	EPS next 5Y	18.87%	ROE	-42.68%	52W High	7.00 -54.71%	Perf Year	-9.17%
Cash/sh	1.47	P/FCF	-	EPS past 3/5Y	31.76% 34.33%	ROIC	-28.36%	52W Low	2.52 25.75%	Perf 3Y	2.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.47% 5.55%	Perf 5Y	-78.14%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	63.85%	Oper. Margin	-	ATR (14)	0.21	Perf 10Y	-92.76%
Dividend Ex-Date	-	Quick Ratio	12.98	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	43.02	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.98	EPS Q/Q	79.92%	SMA20	-5.29%	Beta	0.13	Target Price	6.37
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-4.56%	Rel Volume	0.90	Prev Close	3.26
Employees	9	LT Debt/Eq	0.00	Earnings	Aug 28 AMC	SMA200	-23.69%	Avg Volume	16.15K	Price	3.17
IPO	Sep 05, 2002	Option/Short	No / Yes	EPS/Sales Surpr.	- -18.01%	Trades		Volume	14,516	Change	-2.76%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-03-25	Downgrade	The Benchmark Company	Speculative Buy → Hold
Dec-12-24	Initiated	Maxim Group	Buy	$8

Jan-30-26 07:25AM	Alterity Therapeutics: Appendix 4C - Q2 FY26 Quarterly Cash Flow Report & Corporate Update (GlobeNewswire)
Jan-21-26 07:25AM	Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 (GlobeNewswire)
Nov-12-25 07:25AM	Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference (GlobeNewswire)
Nov-10-25 07:25AM	Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System (GlobeNewswire) +8.27%
Oct-31-25 07:25AM	Alterity Therapeutics: Appendix 4C - Q1 FY26 Quarterly Cash Flow Report (GlobeNewswire) -8.48%
07:25AM	Loading…
Oct-09-25 07:25AM	Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
Oct-02-25 07:35AM	Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire) +6.08%
Sep-30-25 03:01PM	Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434 (Insider Monkey)
Sep-15-25 07:25AM	Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting (GlobeNewswire)
Sep-08-25 07:35AM	Alterity Therapeutics Raises A$20.0 million in Strategic Placement (GlobeNewswire)
Sep-02-25 07:25AM	Alterity Therapeutics to Present at the Biotech Showcase (GlobeNewswire)
Aug-17-25 01:54AM	Alterity Therapeutics Limited (ATHE) Announces Positive Topline Data From Phase 2 Trial of ATH434 in Multiple System Atrophy (Insider Monkey)
Jul-30-25 07:25AM	Appendix 4C - Q4 FY25 Quarterly Cash Flow Report (GlobeNewswire)
Jul-28-25 07:25AM	Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy (GlobeNewswire) -14.81%
Jul-24-25 07:25AM	Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study (GlobeNewswire) +13.76%
07:25AM	Loading…
Jun-23-25 07:25AM	Alterity Therapeutics to Provide Corporate Update in Fireside Chat (GlobeNewswire)
May-12-25 07:35AM	Alterity Therapeutics Prominently Featured at the International MSA Congress (GlobeNewswire) -8.54%
May-07-25 08:16AM	Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress (GlobeNewswire)
May-05-25 07:35AM	Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy (GlobeNewswire) +26.45%
Apr-30-25 07:35AM	Appendix 4C Q3 FY25 Quarterly Cash Flow Report (GlobeNewswire)
Apr-28-25 07:35AM	Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium (GlobeNewswire)
Apr-10-25 07:35AM	Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting (GlobeNewswire)
Apr-03-25 07:35AM	Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting (GlobeNewswire) -5.39%
Mar-27-25 07:25AM	Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy (GlobeNewswire)
Feb-10-25 07:25AM	Alterity Therapeutics Raises A$40.0 million in Placement (GlobeNewswire) +8.71%
Jan-30-25 07:35AM	Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy (GlobeNewswire) +57.04%
Jan-24-25 07:35AM	Appendix 4C Q2 FY25 Quarterly Cash Flow Report (GlobeNewswire) -11.98%
Jan-10-25 07:35AM	Alterity CEO says filled with optimism for 2025 (TipRanks)
Jan-09-25 07:25AM	Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones (GlobeNewswire)
Dec-04-24 07:35AM	Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy (GlobeNewswire) +17.49%
07:25AM	Loading…
Nov-19-24 07:25AM	Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary (GlobeNewswire)
Nov-12-24 07:35AM	Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium (GlobeNewswire)
Nov-06-24 07:35AM	Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434 (GlobeNewswire)
Oct-31-24 07:35AM	Appendix 4C Q1 FY25 Quarterly Cash Flow Report (GlobeNewswire)
Oct-14-24 07:35AM	Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024 (GlobeNewswire)
Oct-11-24 07:35AM	Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting (GlobeNewswire)
Oct-02-24 07:35AM	Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
Sep-30-24 07:35AM	Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer (GlobeNewswire)
Sep-23-24 07:35AM	Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
Jul-31-24 07:35AM	Appendix 4C Q4 FY24 Quarterly Cash Flow Report (GlobeNewswire)
Jul-24-24 07:35AM	Alterity Therapeutics to Present at MST Financial Webinar (GlobeNewswire)
Jul-18-24 11:01AM	Alterity (ATHE) Up on Interim Data From Advance MSA Study (Zacks) -11.01%
Jul-17-24 07:35AM	Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire) +6.34%
Jun-12-24 07:22PM	Alterity Therapeutics to Present at the MST Access 'Hidden Gems in Life Sciences' Webinar (GlobeNewswire)
May-29-24 07:21PM	Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study (GlobeNewswire)
May-08-24 07:25AM	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review (GlobeNewswire)
Apr-30-24 07:25AM	Appendix 4C Q3 FY24 Quarterly Cash Flow Report (GlobeNewswire)
Apr-29-24 07:25AM	Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia (GlobeNewswire) -12.55%
Apr-17-24 07:25AM	Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Apr-10-24 07:25AM	Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 (GlobeNewswire) +14.66%
Mar-26-24 10:25AM	Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund (GlobeNewswire) +5.26%
Feb-20-24 10:25AM	Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
Feb-06-24 07:25AM	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review (GlobeNewswire)
Jan-29-24 07:24AM	Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week (GlobeNewswire) +5.53%
Jan-22-24 07:25AM	Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones (GlobeNewswire)
Dec-21-23 12:30AM	Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer (GlobeNewswire)
Dec-04-23 04:35PM	Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress (GlobeNewswire) +153.01% -22.86%
02:15PM	Why Is Alterity Therapeutics (ATHE) Stock Up 150% Today? (InvestorPlace)
07:25AM	Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease (GlobeNewswire)
Nov-27-23 07:25AM	Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy (GlobeNewswire) -6.49%
Nov-16-23 07:25AM	Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434 (GlobeNewswire)
Nov-08-23 07:25AM	Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire) +12.77%
Oct-30-23 07:25AM	Appendix 4C Q1 FY24 Quarterly Cash Flow Report (GlobeNewswire) -5.98%
Aug-31-23 07:25AM	Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder (GlobeNewswire)
Aug-23-23 07:25AM	Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinsons and Alzheimers (GlobeNewswire)
Aug-22-23 07:25AM	Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinsons Disease and Movement Disorders (GlobeNewswire)
Aug-15-23 07:25AM	Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund (GlobeNewswire)
Jul-31-23 07:52AM	Appendix 4C Q4 FY23 Quarterly Cash Flow Report (GlobeNewswire)
Jul-26-23 07:25AM	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned (GlobeNewswire) +6.49%
Jun-21-23 07:25AM	Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023 (GlobeNewswire)
May-30-23 07:25AM	Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder (GlobeNewswire) +6.51%
May-19-23 07:25AM	Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023 (GlobeNewswire)
May-10-23 07:25AM	Appendix 4C Q3 FY23 Quarterly Cash Flow Report (GlobeNewswire)
07:25AM	Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire)
Apr-26-23 07:25AM	Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology (GlobeNewswire)
Apr-04-23 07:25AM	Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire)
Mar-16-23 07:25AM	Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire) +6.70%
Mar-14-23 07:25AM	Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimers Disease (GlobeNewswire) -7.14%
Mar-08-23 07:25AM	Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire)
Feb-16-23 04:44PM	Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial (GlobeNewswire) +7.64%
Jan-31-23 07:25AM	Appendix 4C - Q2 FY23 Quarterly Cash Flow Report (PR Newswire) -5.78%
Jan-30-23 07:25AM	Alteritys ATH434 Prevents Loss of Brain Cells in Parkinsons Disease Animal Model (GlobeNewswire) +6.14%
Jan-25-23 07:25AM	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy (GlobeNewswire)
Jan-20-23 09:40AM	Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-09-23 10:25AM	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy (PR Newswire)
Jan-06-23 07:25AM	Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) (PR Newswire)
Jan-03-23 10:25AM	Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (PR Newswire)
Dec-29-22 10:25AM	Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office (PR Newswire) +16.91%
Nov-07-22 10:25AM	Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting (PR Newswire)
Oct-28-22 07:25AM	Appendix 4C - Q1 FY23 Quarterly Cash Flow Report (PR Newswire)
Oct-26-22 07:25AM	Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting (PR Newswire)
Oct-13-22 10:25AM	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy (PR Newswire)
Sep-26-22 07:25AM	Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders (PR Newswire)
Sep-20-22 07:25AM	Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy (PR Newswire) -10.71%
Aug-25-22 07:25AM	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe (PR Newswire)
Aug-08-22 04:00PM	Is Alterity Therapeutics (ASX:ATH) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jul-22-22 07:25AM	Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report (PR Newswire)
Jul-06-22 11:00AM	Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (PR Newswire)
Jun-24-22 08:35AM	Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing (GlobeNewswire)
Jun-23-22 11:00AM	Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy (PR Newswire) +5.24%

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson's, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATHE

Alterity Therapeutics Ltd ADR

Upgrade your FINVIZ experience